KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy

Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest cancers in oncology because of its increasing incidence and poor survival rate. More than 90% of PDAC patients are KRAS mutated (KRASmu), with KRASG12D and KRASG12V being the most common mutations. Despite this critical role, its...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurreri, Enrico, Genovese, Giannicola, Perelli, Luigi, Agostini, Antonio, Piro, Geny, Carbone, Carmine, Tortora, Giampaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253344/
https://www.ncbi.nlm.nih.gov/pubmed/37298264
http://dx.doi.org/10.3390/ijms24119313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253344/
https://www.ncbi.nlm.nih.gov/pubmed/37298264
http://dx.doi.org/10.3390/ijms24119313

Ejemplares similares